Top Injectable Manufacturer in Gabon – Reliable Pharmaceutical Solutions
- Maulik Sudani
- 3 days ago
- 10 min read
Last Updated: September 3, 2026
TL;DR: Gabon answers the question we always ask first — does the country keep a list of regulators it will rely on, and is India on it — with no list at all. The new Agence Nationale du Médicament et des Autres Produits de Santé, created by ordinance in October 2023 and given its statutes in January 2025, publishes a single dossier checklist for the Autorisation de Mise sur le Marché Gabonais and no reliance or abridged pathway; its guidelines page is empty and none of its thirty legal texts concerns recognition of foreign authorities. The CEMAC harmonisation regulation exists and the regional body OCEAC runs pilot joint evaluations, but no common authorisation is in force. The route is therefore the national one: a French-language CTD on USB, a GMP certificate under three years old for the finished-product site and for every active-ingredient site, fifty samples, a declared ex-factory price in CFA francs, a fee of 500,000 FCFA for an imported medicine, and a five-year authorisation. The commercial gate is the Office Pharmaceutique National, the state central purchasing body that supplies public hospitals and also private wholesalers, and the CNAMGS insurance fund, whose reimbursement rules were rewritten in 2025 and are still being contested.
Key Takeaways
No reliance list exists, so the origin-country file must be complete. The ANMAPS checklist asks for a copy of the country-of-origin authorisation with a certified French translation, a WHO-format certificate of a pharmaceutical product, the list of countries where the product is registered and, where it applies, WHO prequalification. Nothing conditions acceptance on the origin regulator being on a list, because there is no list; whether CDSCO would be treated as a reference authority is unknown in both directions.
The dossier is French and electronic. Module 1 on paper and USB, Modules 2 to 5 in CTD format on USB only, the summary of product characteristics in French in editable form, a GMP certificate less than three years old for the finished-product manufacturer and each active-ingredient manufacturer, the manufacturing licence, the CVs of the heads of production and quality control, fifty commercial-pack samples with certificates of analysis, and an attestation of the ex-factory wholesale price in CFA francs.
The instruments and fees are published; the timeline is not. The AMMG is valid for five years and a temporary commercial authorisation for two; the fee order of the Ministry of Health sets 500,000 FCFA for registration of an imported medicine, 350,000 for renewal, 100,000 for a major variation and 250,000 for a temporary authorisation. No statutory review period is published anywhere we could read, and we state none.
The buyer is the State's central purchasing body and the insurance fund. The Office Pharmaceutique National buys under the public procurement code and supplies public hospitals, national programmes and private wholesalers from four bulk warehouses and nine regional depots. CNAMGS reimbursement was reset in March 2025 to 80%, 90% and 100% by category, with generics favoured over branded products, and the new reimbursable list was contested and suspended within months. Out-of-pocket spending is 17.3% of health expenditure, low for the region.
Introduction: Why Gabon Demands a Premium Injectable Manufacturer in Gabon
Every market in this series opens with the same question: does the country publish a list of regulatory authorities whose decisions it will lean on, and is India's CDSCO among them? Gabon is the clearest case yet of the answer being no list at any layer. The regulator is the Agence Nationale du Médicament et des Autres Produits de Santé, ANMAPS, an independent administrative authority under the Ministry of Health created by Ordinance No. 0004/PR/2023 of 24 October 2023, ratified by Law No. 006/2023 of 26 January 2024 and given its statutes by Decree No. 0091/PR/MS of 31 January 2025; it succeeds the former Direction du Médicament et de la Pharmacie and sits on the 2011 ordinance organising the pharmaceutical sector. Its website publishes one page on the registration of medicines, the homologation checklist for the Autorisation de Mise sur le Marché Gabonais, and that page contains no reliance route, no abridged procedure and no reference authorities. The guidelines section of the site is empty. Of the thirty legal texts the agency lists, only the order on variations and the order on fees concern the authorisation procedure, and neither names a foreign authority.
The regional layer does not supply a list either. Gabon belongs to CEMAC, and Community Regulation No. 05/13 on the harmonised registration of medicines exists; we could not read its text. The regional health body OCEAC runs joint evaluation workshops under it — the Brazzaville session of December 2025 assessed fewer than fifteen dossiers selected through a call in August — and those are a pilot, not a route a company can plan around, so the national AMMG remains the operative gate. What the checklist does ask for is the origin-country authorisation with a certified French translation, a WHO-model certificate of a pharmaceutical product, the list of countries where the product is registered, and WHO prequalification where it applies. We therefore do not say that India is on or off any Gabonese list, because there is none; we say that a premium injectable manufacturer in Gabon is one whose Indian authorisation, CPP and GMP evidence are complete enough to stand on their own in French.
What Sets a World-Class Injectable Manufacturer in Gabon Apart
The dossier is French-language and electronic, and that settles more than it seems. The application is addressed to the Minister of Health through the Director-General of ANMAPS and signed by a responsible pharmacist; Module 1 goes in on paper and on USB, Modules 2 to 5 in CTD format on USB only, with the summary of product characteristics in French in an editable file and Module 5 carrying the biowaiver justification where a generic claims one. The checklist requires the certificate of opening of a pharmaceutical establishment for the authorisation holder, for the operating company and for the finished-product manufacturer, and a description of the commercial links between them. Whether the operating company must itself be established in Gabon is governed by an order on pharmaceutical establishments that we located but did not read, so we neither assert nor deny it; commercially, a Gabonese responsible pharmacist and importer are how the file is signed and how the product is sold. Fifty commercial-pack samples with certificates of analysis accompany a registration and thirty a renewal, and an attestation of the ex-factory wholesale price in CFA francs is part of the file, which means the price is declared before the product is authorised.
The GMP requirement is stricter on paper than in many larger markets. The checklist wants a GMP certificate less than three years old for the finished-product manufacturer and for each manufacturer of an active ingredient, the manufacturing licence, the curricula vitae of the heads of production and quality control, and a copy of the notification of a favourable opinion for the laboratory visited — wording that implies an inspection step whose conditions and cost are not published, so we do not describe them. The instruments are clear: the AMMG is valid for five years and the temporary commercial authorisation, on the same dossier, for two. The fee order of the Ministry of Health, which we read as a scanned document, sets 500,000 FCFA for registration of an imported medicine against 300,000 for a locally made one, 350,000 for renewal of an imported product, 100,000 for a major and 50,000 for a minor variation, and 250,000 for a temporary authorisation. What is not published anywhere we could find is a review timeline, and the figures that circulate on consultancy sites are not something we repeat. The process is described as submission, expert analysis, commission, authorisation, and a supplier should plan for the commission calendar rather than a statutory clock.
Quality Systems Behind Every Injectable Supplied to Gabon
For a sterile injectable the evidence behind the GMP certificate is what will be tested if the laboratory-visit step is exercised: aseptic process simulation records for the ISO Class 5 filling line, environmental monitoring trends, container-closure integrity, sterility and bacterial endotoxin testing by LAL, particulate matter, validated HPLC and GC assay and impurity methods, and ICH Q1A stability generated for a hot and humid climate rather than extrapolated. Because the checklist also asks for the active-ingredient manufacturer's GMP certificate, the supplier must be able to produce its API supplier's certificate, under three years old, alongside its own — a detail that trips up manufacturers who treat the API file as somebody else's.
Two further facts frame the file. Gabon does not appear on the WHO's August 2026 list of authorities operating at maturity level 3 or 4, which tells you only that it is not listed, not what its benchmarked level is; and it ratified the African Medicines Agency treaty in October 2021 as the fourteenth state to do so, while neither Gabon nor India is a PIC/S participating authority. ANMAPS announced ISO 9001 certification of its own management system in January 2026 and has been receiving evaluator training on bioequivalence and biosimilar dossiers through a French cooperation programme; a young agency building its assessment capacity is one that will ask more questions, not fewer, and the French-language quality of the answers will matter.
Looking for a sterile injectable manufacturing partner? Talk to Farbe Firma about your market entry.
Why Farbe Firma is the Trusted Injectable Manufacturer in Gabon for Global Buyers
Farbe Firma Pvt Ltd is a WHO-GMP certified sterile injectable manufacturer and CDMO based in Gujarat, India, filling under ISO Class 5 conditions and exporting to more than thirty countries. We build dossiers in CTD and ACTD format and we are used to producing them in French for francophone Africa: Module 1 on paper and USB, Modules 2 to 5 electronic, the summary of product characteristics in editable French, the Indian authorisation with a certified translation, the WHO-format CPP, our own GMP certificate and our active-ingredient suppliers' certificates within three years, fifty samples with certificates of analysis and the ex-factory price attestation in CFA francs. Our analytical package of HPLC, GC, LAL, Karl Fischer and ICH Q1A/Q1B stability is written so that an expert analysis has nothing to return, and we say plainly that Gabon offers no reliance shortcut and that a complete national file is the whole strategy.
The bilateral relationship is broad and the pharmaceutical trade is small but growing. India's Ministry of External Affairs brief of February 2025 records joint commission and foreign-service training agreements and an industry memorandum, and Gabon joined the Commonwealth in June 2022; pharmaceuticals were about USD 1.6 million and the sixth-ranked Indian export in 2023–24, far behind Gabon's mineral fuels, ores and timber flowing the other way, and we found no health or pharmaceutical memorandum and no cooperation between ANMAPS and CDSCO. UN Comtrade puts India-reported pharmaceutical exports to Gabon at USD 2.33 million in 2022, USD 2.12 million in 2023, USD 3.48 million in 2024 and USD 3.75 million in 2025, while Gabon reports imports of pharmaceutical products from India of USD 17.51 million in 2022 and USD 20.37 million in 2023. The two series differ by a factor of six to nine, which usually reflects goods of Indian origin arriving through European wholesalers; we report the gap and do not explain it.
Where the money is: Gabon has 2.59 million people, gross national income per capita of USD 8,090 in 2025 — an upper-middle-income figure — current health expenditure of about USD 253 per person and 3.1% of GDP in 2023, and life expectancy of 68.5 years. Out-of-pocket payments were 17.3% of health expenditure in 2023, which is low for the region and reflects the insurance fund. The Office Pharmaceutique National, a state company created in 1995 and reorganised by ordinance in 2021, is the national central purchasing body: it buys under the public procurement code through international and restricted tenders, negotiated contracts and quotations, manages stock on an enterprise system, holds four bulk warehouses and one for the HIV and TB programmes, and supplies nine regional depots twice a year. Its clients are the university, regional and district hospitals, the health centres and national programmes, and also private wholesalers, polyclinics and NGOs; whether it is the mandatory supplier to public hospitals is not something we verified from a legal text, and we found no tender notices published. The CNAMGS fund's reimbursement was reset by ministerial order in March 2025 to 80% for common illnesses, 90% for long-term conditions and 100% for pregnant women, with generics by international non-proprietary name reimbursed at those rates and branded products at half; the accompanying list of reimbursable products was contested by pharmacies and suspended, and a ministerial meeting in November 2025 convened the fund, ANMAPS and the OPN to rebuild it. Tuberculosis incidence is high at 371 per 100,000, and the injectable demand is the general hospital formulary — antibiotics, anaesthetics, emergency, maternal and oncology medicines.
Explore Farbe Firma: Products | Global Reach | About Us
Frequently Asked Questions (FAQ)
Is India on Gabon's list of recognised regulatory authorities?
There is no list. The ANMAPS registration checklist contains no reliance or abridged pathway and names no reference authorities; its guidelines page is empty and none of its thirty legal texts concerns recognition of foreign regulators. The CEMAC harmonisation regulation exists but no common authorisation is in force. What Gabon asks for is the origin-country authorisation with a certified French translation, a WHO-format CPP, the list of countries where the product is registered and WHO prequalification where applicable. Whether CDSCO would be treated as a reference authority is unknown in both directions.
What does a Gabonese marketing authorisation application require?
An application to the Minister of Health through the ANMAPS Director-General, signed by a responsible pharmacist: Module 1 on paper and USB, Modules 2 to 5 in CTD format on USB in French, the SmPC in editable French, certificates of opening of a pharmaceutical establishment for the holder, the operating company and the manufacturer, a GMP certificate under three years old for the finished-product site and each API site, the manufacturing licence, CVs of the production and quality-control heads, fifty samples with certificates of analysis, the origin-country authorisation and CPP, and an ex-factory price attestation in CFA francs.
What are the fees and how long is the authorisation valid?
The Ministry of Health fee order sets 500,000 FCFA for registration of an imported medicine, 350,000 for renewal, 100,000 for a major variation, 50,000 for a minor one and 250,000 for a temporary commercial authorisation. The AMMG is valid for five years and the temporary authorisation for two. No statutory review period is published, and we do not state one.
Can we use a CEMAC or regional registration to enter Gabon?
Not in practice. Community Regulation No. 05/13 provides a harmonised framework and OCEAC runs pilot joint evaluations — the December 2025 session assessed fewer than fifteen dossiers — but no common CEMAC authorisation is in force and whether a joint evaluation leads automatically to a national AMMG is not established. Plan on the national procedure.
How do we sell to the public sector in Gabon?
Through the Office Pharmaceutique National, the state central purchasing body that procures under the public procurement code by international and restricted tenders, negotiated contracts and quotations, and supplies the public hospitals, health centres, national programmes and also private wholesalers from four bulk warehouses and nine regional depots. A Gabonese responsible pharmacist and importer are the practical partner. CNAMGS reimbursement rules were reset in 2025 and the reimbursable list is being rebuilt, so generic positioning by INN matters.
Technically Reviewed By: Maulik Sudani | Jignasu Sudani (Technical Expert)
Website: www.farbefirma.org | Email: director@farbefirma.org | Address: Gujarat, INDIA
Request a Quote | View Products | FAQ | Blog
Comments